MX2021006702A - Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen. - Google Patents

Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen.

Info

Publication number
MX2021006702A
MX2021006702A MX2021006702A MX2021006702A MX2021006702A MX 2021006702 A MX2021006702 A MX 2021006702A MX 2021006702 A MX2021006702 A MX 2021006702A MX 2021006702 A MX2021006702 A MX 2021006702A MX 2021006702 A MX2021006702 A MX 2021006702A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
compositions containing
crystalline forms
mcl
inhibitor
Prior art date
Application number
MX2021006702A
Other languages
English (en)
Inventor
Michael Lynch
Baets Emilie De
Julien Auvray
Nicolas Leblanc
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2021006702A publication Critical patent/MX2021006702A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Formas cristalinas del Compuesto A: (ver Fórmula) caracterizadas por su diagrama de difracción de rayos X de polvo, espectro de RMN 13C en estado sólido, espectro de MIR y espectro de Raman y composiciones farmacéuticas que las contienen.
MX2021006702A 2018-12-06 2019-12-05 Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen. MX2021006702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (en) 2018-12-06 2019-12-05 New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.

Publications (1)

Publication Number Publication Date
MX2021006702A true MX2021006702A (es) 2021-07-07

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006702A MX2021006702A (es) 2018-12-06 2019-12-05 Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen.

Country Status (21)

Country Link
US (1) US20220017533A1 (es)
EP (1) EP3891156B1 (es)
JP (1) JP2022511495A (es)
KR (1) KR20210100148A (es)
CN (1) CN113166169A (es)
AR (1) AR117255A1 (es)
AU (1) AU2019391329A1 (es)
BR (1) BR112021010072A2 (es)
CA (1) CA3121363A1 (es)
DK (1) DK3891156T3 (es)
EA (1) EA202191534A1 (es)
FI (1) FI3891156T3 (es)
IL (1) IL283656A (es)
LT (1) LT3891156T (es)
MA (1) MA54379B1 (es)
MX (1) MX2021006702A (es)
PT (1) PT3891156T (es)
RS (1) RS65047B1 (es)
SI (1) SI3891156T1 (es)
TW (1) TW202039511A (es)
WO (1) WO2020115183A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
TW202317200A (zh) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Ｍｃｌ－１抑制劑與抗體藥物接合物之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CA3121363A1 (en) 2020-06-11
EA202191534A1 (ru) 2021-10-27
JP2022511495A (ja) 2022-01-31
MA54379B1 (fr) 2023-12-29
AR117255A1 (es) 2021-07-21
KR20210100148A (ko) 2021-08-13
PT3891156T (pt) 2024-01-16
DK3891156T3 (da) 2024-02-19
EP3891156B1 (en) 2023-11-15
AU2019391329A1 (en) 2021-07-01
BR112021010072A2 (pt) 2021-08-24
WO2020115183A1 (en) 2020-06-11
MA54379A (fr) 2021-10-13
SI3891156T1 (sl) 2024-03-29
FI3891156T3 (fi) 2024-02-07
EP3891156A1 (en) 2021-10-13
TW202039511A (zh) 2020-11-01
CN113166169A (zh) 2021-07-23
RS65047B1 (sr) 2024-02-29
LT3891156T (lt) 2023-12-27
US20220017533A1 (en) 2022-01-20
IL283656A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
UA83720C2 (ru) Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
MY141306A (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
GEP20094576B (en) New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
CR20210032A (es) Compuestos
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
PH12021550790A1 (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
MX2021006702A (es) Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen.
EA201891023A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
MY196762A (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
UA89905C2 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ
CR20220116A (es) Compuestos heterocíclicos
GEP20237490B (en) Polymorphs
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
EA202090281A1 (ru) Фармацевтическое соединение, способ его получения и применения в качестве лекарственного средства
EP4289844A3 (en) A process for making palbociclib
TNSN05076A1 (en) New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
MY138209A (en) New (y) crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it.
MY142738A (en) Preparation method of a novel beta crystalline form of perindopril tert-butylamine salt
TNSN05077A1 (en) New y crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
GEP20094652B (en) New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it